A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Exclusion Criteria

• •Have currently received ixekizumab for more than 4 months or less than 2 months.
• •Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
• •Are currently enrolled in any other clinical study.
• •Other exclusions
• •Have a known hypersensitivity to tirzepatide or to any of its component.
• •Have a personal or family history of medullary thyroid cancer.
• •Have multiple endocrine neoplasia type 2.
• •Have type I diabetes mellitus.
• •Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).
• •Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.
• •Have a history of ketoacidosis or hyperosmolar state/coma.
• •Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.
• •Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.